COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Double Blind, Placebo Controlled Trial of Quetiapine in Anorexia Nervosa, a Dual Site Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00584688
Recruitment Status : Terminated (Lack of Enrollment)
First Posted : January 2, 2008
Last Update Posted : June 18, 2012
University of California, San Diego
Information provided by (Responsible Party):
University of South Florida

Brief Summary:
Research studies raise the possibility that medications such as quetiapine may improve mood or reduce obsessions in people with anorexia nervosa and may even help to normalize appetite. The medication quetiapine also known as seroquel works by activating certain systems in the brain, such as ones known as dopamine and serotonin chemical systems in the brain.

Condition or disease Intervention/treatment Phase
Anorexia Nervosa Drug: quetiapine Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Double Blind, Placebo Controlled Trial of Quetiapine in Anorexia Nervosa, a Dual Site Study
Study Start Date : February 2007
Actual Primary Completion Date : June 2009
Actual Study Completion Date : August 2009

Resource links provided by the National Library of Medicine

Drug Information available for: Quetiapine

Intervention Details:
  • Drug: quetiapine
    quetiapine dosage will be titrated to subject tolerance beginning at 50 mg every 24 hours upwards to 400 mg every 24 hours.

Primary Outcome Measures :
  1. To determine efficacy of seroquel in anorexia nervosa [ Time Frame: 8 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Must be aged 18-65
  • Must be at least 15% below ideal body weight

Exclusion Criteria:

  • Allergy to quetiapine
  • Diagnosis of schizophrenia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00584688

Layout table for location information
United States, Florida
University of South Floirda
Tampa, Florida, United States, 33613
Sponsors and Collaborators
University of South Florida
University of California, San Diego
Additional Information:
Layout table for additonal information
Responsible Party: University of South Florida Identifier: NCT00584688    
Other Study ID Numbers: 0825
First Posted: January 2, 2008    Key Record Dates
Last Update Posted: June 18, 2012
Last Verified: March 2009
Keywords provided by University of South Florida:
Additional relevant MeSH terms:
Layout table for MeSH terms
Anorexia Nervosa
Signs and Symptoms, Digestive
Signs and Symptoms
Feeding and Eating Disorders
Mental Disorders
Quetiapine Fumarate
Antidepressive Agents
Psychotropic Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs